
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is well positioned fundamentally because Revtorpyk/gedatolisib has already validated its mechanism in Phase III, with approval in July 2026 for 2L+ HR+/HER2- disease and strong data in both PIK3CA-wildtype and mutant populations supporting a broad, mutation-agnostic label expansion. The commercial case is reinforced by an estimated ~60% of the 2L population being PIK3CA-wildtype at launch, survey-based expectations for ~39% peak penetration, and management’s ability to support adoption through completed payer engagement, distribution, and a 120-day payment window. Beyond the breast-cancer base, the ongoing VIKTORIA-2 and mCRPC programs provide additional upside, while the company’s path to roughly $2.4B peak sales across WT and mutant disease underpins a positive outlook.
Bears say
Celcuity is a clinical-stage biotech with no approved revenue base, so its valuation depends heavily on gedatolisib executing across late-stage trials and a launch that still faces reimbursement, manufacturing, and formulary friction. The bear case centers on adoption barriers rather than biology alone: weekly IV dosing, stomatitis, and buy-and-bill delays could slow uptake, while community oncologists may favor convenient oral competitors even at modest efficacy tradeoffs. Fundamentally, the company also faces a high clinical bar in HR+/HER2- breast cancer, where existing CDK4/6 inhibitor plus aromatase inhibitor regimens have shown median PFS of 25-28 months and multiple Phase 3 efforts have failed to improve on standard of care.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Celcuity (CELC) Forecast
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares